BeOne Medicines (ONC) is back in focus after InSysBio extended its collaboration with the company to apply mechanistic translational modeling, aimed at refining dose selection and clinical study design in oncology programs.

That extended collaboration and a run of supportive analyst commentary have come alongside firm share price momentum. A 1 month share price return of 6.01% and a 1 year total shareholder return of 58.35% signal strong recent interest, following a weaker 5 year total shareholder return decline of 7.05%.

If oncology is on your radar after reading about BeOne Medicines, it might be worth scanning our list of 26 healthcare AI stocks as another way to spot potential opportunities in this space.

With BeOne Medicines trading at $353.92, alongside an indicated 61% intrinsic discount and a 15% gap to the average analyst target of $405.42, investors may ask whether there is still a buying opportunity here or whether the market is already pricing in future growth.

Most Popular Narrative: 12% Undervalued

With BeOne Medicines last closing at $353.92 against a narrative fair value of $404.19, the current price sits below what that narrative implies.

The company's robust pipeline, including multiple late-stage oncology assets (over 20 Phase III trials and >10 proof-of-concept readouts expected in the next 18 months), leverages internal R&D capabilities and the GlueXplorer platform to rapidly develop targeted, personalized medicines that are well aligned with the shift toward precision therapeutics. This supports the potential for long-term earnings and margin expansion as products commercialize. Value inflection points are approaching as multiple pivotal trial readouts and global filings (for sonrotoclax, BTK CDAC, and solid tumor assets) are expected by 2026. These milestones line up with increased adoption and reimbursement potential driven by broader healthcare investment and the possibility of upside to future earnings if breakthrough therapies achieve approval.

Interested in why this narrative thinks BeOne can support a higher price tag? Revenue, margins, and future earnings multiples all carry bold embedded assumptions.

Result: Fair Value of $404.19 (UNDERVALUED)

However, you still need to weigh the risk that late stage trials or regulatory decisions disappoint, or that competition in BTK and protein degradation therapies intensifies.

Build Your Own BeOne Medicines Narrative

If you are not fully on board with this view, or prefer to lean on your own research, you can build a custom BeOne Medicines story in just a few minutes. To begin, use Do it your way.

A great starting point for your BeOne Medicines research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If BeOne Medicines has sharpened your focus, do not stop here. Use our screeners to spot other opportunities that might fit your approach.

• Target potential value opportunities early by reviewing our list of screener containing 25 high quality undiscovered gems that combine strong fundamentals with limited market attention.
• Strengthen your search for resilience by checking out companies in the 86 resilient stocks with low risk scores that score well on our risk metrics.
• Focus on quality at a compelling price by scanning the 53 high quality undervalued stocks that our models flag as potentially trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.